$0.2091
-0.0081-3.73%
At close: Feb 12, 4:00 PM EST
$0.2197
0.01065.07%
After Hours: 7:27 PM EST
Comments
Loading...
Virax Biolabs Group Ltd Analyst Ratings
VRAXNASDAQ
Virax Biolabs Group Analyst Ratings and Price Targets | NASDAQ:VRAX | Benzinga
Virax Biolabs Group Ltd has a consensus price target of $1 based on the ratings of 1 analysts. The high is $1 issued by HC Wainwright & Co. on January 9, 2026. The low is $1 issued by HC Wainwright & Co. on January 9, 2026. The 2 most-recent analyst ratings were released by HC Wainwright & Co. on January 9, 2026 and March 31, 2025, respectively. With an average price target of $2 between HC Wainwright & Co., there's an implied 810.33% upside for Virax Biolabs Group Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Virax Biolabs Group
FAQ
What is the target price for Virax Biolabs Group (VRAX) stock?
The latest price target for Virax Biolabs Group (NASDAQ:VRAX) was reported by HC Wainwright & Co. on January 9, 2026. The analyst firm set a price target for $1.00 expecting VRAX to rise to within 12 months (a possible 355.17% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Virax Biolabs Group (VRAX)?
The latest analyst rating for Virax Biolabs Group (NASDAQ:VRAX) was provided by HC Wainwright & Co., and Virax Biolabs Group reiterated their buy rating.
When was the last upgrade for Virax Biolabs Group (VRAX)?
There is no last upgrade for Virax Biolabs Group
When was the last downgrade for Virax Biolabs Group (VRAX)?
There is no last downgrade for Virax Biolabs Group.
When is the next analyst rating going to be posted or updated for Virax Biolabs Group (VRAX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Virax Biolabs Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Virax Biolabs Group was filed on January 9, 2026 so you should expect the next rating to be made available sometime around January 9, 2027.
Is the Analyst Rating Virax Biolabs Group (VRAX) correct?
While ratings are subjective and will change, the latest Virax Biolabs Group (VRAX) rating was a reiterated with a price target of $3.00 to $1.00. The current price Virax Biolabs Group (VRAX) is trading at is $0.22, which is out of the analyst’s predicted range.
